Protara Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Protara Therapeutics (Nasdaq: TARA) said management will present at two investor conferences in late February and early March 2026.
Virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference is scheduled for Feb 26, 2026 at 2:40 PM ET, and an in-person fireside chat at TD Cowen 46th Annual Health Care Conference is scheduled for Mar 3, 2026 at 2:30 PM ET in Boston. Live webcasts and limited-time archives are available via the company’s Events and Presentations webpage.
Positive
- None.
Negative
- None.
News Market Reaction – TARA
In the Feb 19 session, TARA gained 7.20%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.0% during that session. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
- Oppenheimer 36th Annual Healthcare Life Sciences Conference. A fireside chat will take place virtually on Thursday, February 26 at 2:40 pm ET.
- TD Cowen 46th Annual Health Care Conference. A fireside chat will take place on Tuesday, March 3 at 2:30 pm ET in Boston.
A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
